Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Innate immune response to Rift Valley fever virus in goats.

Nfon CK, Marszal P, Zhang S, Weingartl HM.

PLoS Negl Trop Dis. 2012;6(4):e1623. doi: 10.1371/journal.pntd.0001623. Epub 2012 Apr 24.

2.

Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.

Terasaki K, Tercero BR, Makino S.

Virus Res. 2016 May 2;216:55-65. doi: 10.1016/j.virusres.2015.05.012. Epub 2015 May 27. Review.

3.

Novel approaches to develop Rift Valley fever vaccines.

Indran SV, Ikegami T.

Front Cell Infect Microbiol. 2012 Oct 26;2:131. doi: 10.3389/fcimb.2012.00131. eCollection 2012. Review.

4.

Molecular biology and genetic diversity of Rift Valley fever virus.

Ikegami T.

Antiviral Res. 2012 Sep;95(3):293-310. doi: 10.1016/j.antiviral.2012.06.001. Epub 2012 Jun 16. Review.

5.

Towards a better understanding of Rift Valley fever epidemiology in the south-west of the Indian Ocean.

Balenghien T, Cardinale E, Chevalier V, Elissa N, Failloux AB, Jean Jose Nipomichene TN, Nicolas G, Rakotoharinome VM, Roger M, Zumbo B.

Vet Res. 2013 Sep 9;44:78. doi: 10.1186/1297-9716-44-78. Review.

6.

Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe.

Mansfield KL, Banyard AC, McElhinney L, Johnson N, Horton DL, Hernández-Triana LM, Fooks AR.

Vaccine. 2015 Oct 13;33(42):5520-5531. doi: 10.1016/j.vaccine.2015.08.020. Epub 2015 Aug 19. Review.

7.

[Rift Valley fever].

Pépin M; avec la participation de la CIRE Réunion-Mayotte et l'Institut de Veille Sanitaire (InVS).

Med Mal Infect. 2011 Jun;41(6):322-9. doi: 10.1016/j.medmal.2010.12.010. Epub 2011 Feb 3. Review. French.

PMID:
21295425
8.

Understanding Rift Valley fever: contributions of animal models to disease characterization and control.

Lorenzo G, López-Gil E, Warimwe GM, Brun A.

Mol Immunol. 2015 Jul;66(1):78-88. doi: 10.1016/j.molimm.2015.02.001. Epub 2015 Feb 26. Review.

PMID:
25725948
9.

Rift Valley fever trasmission dynamics described by compartmental models.

Danzetta ML, Bruno R, Sauro F, Savini L, Calistri P.

Prev Vet Med. 2016 Nov 1;134:197-210. doi: 10.1016/j.prevetmed.2016.09.007. Epub 2016 Sep 11. Review.

PMID:
27707507
10.

The role of wild mammals in the maintenance of Rift Valley fever virus.

Olive MM, Goodman SM, Reynes JM.

J Wildl Dis. 2012 Apr;48(2):241-66. Review.

PMID:
22493102
11.

One Health approach to Rift Valley fever vaccine development.

Kortekaas J.

Antiviral Res. 2014 Jun;106:24-32. doi: 10.1016/j.antiviral.2014.03.008. Epub 2014 Mar 26. Review.

PMID:
24681125
12.

Rift Valley fever virus: strategies for maintenance, survival and vertical transmission in mosquitoes.

Lumley S, Horton DL, Hernandez-Triana LLM, Johnson N, Fooks AR, Hewson R.

J Gen Virol. 2017 May;98(5):875-887. doi: 10.1099/jgv.0.000765. Epub 2017 May 30. Review.

PMID:
28555542
13.

Risk factors associated with human Rift Valley fever infection: systematic review and meta-analysis.

Nicholas DE, Jacobsen KH, Waters NM.

Trop Med Int Health. 2014 Dec;19(12):1420-9. doi: 10.1111/tmi.12385. Epub 2014 Sep 24. Review.

14.

Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Atkins C, Freiberg AN.

Future Virol. 2017 Nov;12(11):651-665. doi: 10.2217/fvl-2017-0060. Epub 2017 Oct 23. Review.

PMID:
29181086
15.

Temperature-sensitive mutations for live-attenuated Rift Valley fever vaccines: implications from other RNA viruses.

Nishiyama S, Ikegami T.

Front Microbiol. 2015 Aug 11;6:787. doi: 10.3389/fmicb.2015.00787. eCollection 2015. Review.

16.

Current Status of Rift Valley Fever Vaccine Development.

Faburay B, LaBeaud AD, McVey DS, Wilson WC, Richt JA.

Vaccines (Basel). 2017 Sep 19;5(3). pii: E29. doi: 10.3390/vaccines5030029. Review.

17.

The risk of Rift Valley fever virus introduction and establishment in the United States and European Union.

Rolin AI, Berrang-Ford L, Kulkarni MA.

Emerg Microbes Infect. 2013 Dec;2(12):e81. doi: 10.1038/emi.2013.81. Epub 2013 Dec 4. Review.

18.

Supplemental Content

Support Center